The DOE Isotope Program is pleased to announce the introduction of routine production and availability of high specific activity copper-67 (Cu-67). This dual-purpose radioisotope has garnered considerable attention in the medical community for its “theranostic” properties, meaning it has emissions suitable for both diagnostic imaging and targeted cancer therapy. The DOE Isotope Program has developed this production capability because there is insufficient domestic supply to meet demand.
Copper-67 (t1/2 = 61.83 hours) is produced at Argonne National Laboratory via a photonuclear reaction at its Low-Energy Accelerator Facility (LEAF). The team at Argonne has developed a process that provides approximately 1 curie to customers per batch, with radionuclidic purity of >99% and a specific activity exceeding 50 curies/milligram (Cu-67/total Cu at EOB). *Note: typically 100% Radiochemical Yield (RCY) with TETA and DOTA at >2 millicuries/nanomole (Cu-67/chelate) 3-days after EOB.
Initially, the DOE IP anticipates routine monthly production of Cu-67 but will adjust this schedule as needed to meet market demand.
We are anticipating a high demand for Cu-67.
Request a Quote for Cu-67
